Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

It's not uncommon to experience side effects in the first few weeks of taking a new antidepressant. Here's what to look out ...

Compared to synthetic drugs, natural plant extracts offer the advantages of being suitable for long-term consumption, having ...

Psychiatrist Joanna Moncrieff indicts her entire industry for falsely pushing deadly drugs as a “treatment” for depression.